These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1822 related items for PubMed ID: 26597926

  • 1. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [Abstract] [Full Text] [Related]

  • 2. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S.
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL.
    BMJ; 2013 Oct 24; 347():f6008. PubMed ID: 24157497
    [Abstract] [Full Text] [Related]

  • 5. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH.
    Ren Fail; 2016 Jul 24; 38(6):849-56. PubMed ID: 27055479
    [Abstract] [Full Text] [Related]

  • 6. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y, Ma X, Zheng J, Jia J, Yan T.
    BMC Nephrol; 2017 Jun 30; 18(1):206. PubMed ID: 28666408
    [Abstract] [Full Text] [Related]

  • 7. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R.
    Int J Cardiol; 2016 Aug 15; 217():128-34. PubMed ID: 27179902
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 15; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 9. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J.
    JAMA Intern Med; 2014 May 15; 174(5):773-85. PubMed ID: 24687000
    [Abstract] [Full Text] [Related]

  • 10. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, Li J, Zhang J, Xu Y, Lu H, Xu D.
    BMC Cardiovasc Disord; 2017 Oct 05; 17(1):257. PubMed ID: 28982370
    [Abstract] [Full Text] [Related]

  • 11. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q, Li Q.
    Kidney Blood Press Res; 2018 Oct 05; 43(3):768-779. PubMed ID: 29794446
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC, Heran BS, Wright JM.
    Cochrane Database Syst Rev; 2014 Aug 22; 2014(8):CD009096. PubMed ID: 25148386
    [Abstract] [Full Text] [Related]

  • 13. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ, van Vark L, Akkerhuis M, Bertrand M, Fox K, Mourad JJ, Boersma E.
    Int J Cardiol; 2015 Feb 15; 181():425-9. PubMed ID: 25569271
    [Abstract] [Full Text] [Related]

  • 14. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL.
    J Am Soc Nephrol; 2023 Dec 01; 34(12):1965-1975. PubMed ID: 37876229
    [Abstract] [Full Text] [Related]

  • 15. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
    Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, Vecchio M, Tognoni G, Craig JC, Pellegrini F, Lucisano G, Hegbrant J, Ariano R, Lamacchia O, Sasso A, Morano S, Filardi T, De Cosmo S, Pugliese G, Procaccini DA, Gesualdo L, Palasciano G, Johnson DW, Tonelli M, Strippoli GFM, Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators.
    J Am Soc Nephrol; 2018 Dec 01; 29(12):2890-2899. PubMed ID: 30420421
    [Abstract] [Full Text] [Related]

  • 16. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug 01; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

  • 17. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJ.
    Am J Kidney Dis; 2021 May 01; 77(5):719-729.e1. PubMed ID: 33246024
    [Abstract] [Full Text] [Related]

  • 18. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R, Boersma E.
    Expert Rev Cardiovasc Ther; 2013 Jun 01; 11(6):705-17. PubMed ID: 23750680
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
    Kunz R, Friedrich C, Wolbers M, Mann JF.
    Ann Intern Med; 2008 Jan 01; 148(1):30-48. PubMed ID: 17984482
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
    Shih CJ, Chen HT, Kuo SC, Li SY, Lai PH, Chen SC, Ou SM, Chen YT.
    CMAJ; 2016 May 17; 188(8):E148-E157. PubMed ID: 27001739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 92.